Trading Report: The Bank of New York Mellon Corp reaches $1,664,000 position of NewLink Genetics Corp. (NLNK)

The Bank of New York Mellon Corp reaches $1,664,000 position  of NewLink Genetics Corp. (NLNK)

Bank of New York Mellon Corp raised its stake in shares of NewLink Genetics Corp. (NASDAQ:NLNK) by 2.0% during the second quarter, Holdings Channel reports. The fund owned 147,733 shares of the company’s stock after buying an additional 2,892 shares during the period. Bank of New York Mellon Corp owned about 0.51% of NewLink Genetics Corp. worth $1,664,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its stake in shares of NewLink Genetics Corp. by 1,176.7% in the first quarter. Renaissance Technologies LLC now owns 726,700 shares of the company’s stock valued at $13,226,000 after buying an additional 669,779 shares in the last quarter. Bogle Investment Management L P DE raised its stake in shares of NewLink Genetics Corp. by 822.2% in the first quarter. Bogle Investment Management L P DE now owns 438,593 shares of the company’s stock valued at $7,982,000 after buying an additional 391,036 shares in the last quarter. Spark Investment Management LLC purchased a new stake in shares of NewLink Genetics Corp. during the first quarter valued at approximately $2,156,000. BlackRock Fund Advisors raised its stake in shares of NewLink Genetics Corp. by 8.5% in the first quarter. BlackRock Fund Advisors now owns 1,185,912 shares of the company’s stock valued at $21,584,000 after buying an additional 92,818 shares in the last quarter. Finally, Teachers Advisors Inc. raised its stake in shares of NewLink Genetics Corp. by 24.8% in the first quarter. Teachers Advisors Inc. now owns 193,336 shares of the company’s stock valued at $3,519,000 after buying an additional 38,400 shares in the last quarter. Hedge funds and other institutional investors own 50.10% of the company’s stock.

NewLink Genetics Corp. (NASDAQ:NLNK) traded up 6.10% during midday trading on Friday, hitting $15.30. The stock had a trading volume of 360,770 shares. NewLink Genetics Corp. has a 12-month low of $9.23 and a 12-month high of $46.34. The stock’s market cap is $443.23 million. The company’s 50-day moving average price is $11.71 and its 200 day moving average price is $12.76.

NewLink Genetics Corp. (NASDAQ:NLNK) last issued its earnings results on Friday, July 29th. The company reported ($1.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by $0.35. NewLink Genetics Corp. had a negative return on equity of 51.33% and a negative net margin of 316.38%. On average, equities research analysts predict that NewLink Genetics Corp. will post ($3.06) earnings per share for the current fiscal year.

Separately, Zacks Investment Research lowered NewLink Genetics Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $23.29.

NewLink Genetics Corp. Company Profile

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Related posts

Leave a Comment